Pfizer announces a revised efficacy rating of 91.3% for its vaccine candidate, down from its original rating of 95%, and affirms that protection afforded by the vaccine lasts for at least six months. Pfizer also announces that the vaccine appeared to provide protection against the 501.V2 variant in 100% of cases during its South African trial run.
Pfizer announces a revised efficacy rating of 91.3% for their vaccine candidate, down from its original rating of 95%, and affirms that protection afforded by the vaccine lasts at least 6 months. Pfizer also announced that the vaccine appeared to provide protection against the 501.V2 variant in 100% of cases during their South African trial run. [https:--www.cnbc.com-2021-04-01-pfizer-covid-vaccine-is-91percent-effective-in-updated-data-protective-against-south-african-variant.html (CNBC)] Pfizer–BioNTech COVID-19 vaccine
Pfizer announces a revised efficacy rating of 91.3% for their vaccine candidate, down from its original rating of 95%, and affirms that protection afforded by the vaccine lasts forat least six months. Pfizer also announces that the vaccine appeared to provide protection against the 501.V2 variant in 100% of cases during their South African trial run.
Pfizer announces a revised efficacy rating of 91.3% for its vaccine candidate, down from its original rating of 95%, and affirms that protection afforded by the vaccine lasts for at least six months. Pfizer also announces that the vaccine appeared to provide protection against the 501.V2 variant in 100% of cases during its South African trial run.
